Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NIAID awards SBIR grant to G-Zero
G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’. Previously in late 2009, the company has also received $0.6m through a phase I
G-Zero will use the award to continue studies towards ‘Organismal Radioprotection through Pharmacological Quiescence’. Previously in late 2009, the company has also received $0.6m through a phase I
Under the agreement, Lundbeck and Proximagen will jointly apply their expertise in CNS drug development. As part of the agreement, a steering committee involving experts from both companies
The double blind, placebo controlled Phase III ATLAS ACS TIMI 51 clinical trial showed a reduction in cardiovascular death, myocardial infarction and stroke in patients with ACS, compared
The trial, TR701-113 will study the possibility of switching tedizolid phosphate as a once-daily intravenous (IV) infusion to once-daily oral therapy in ABSSSI patients. The 113 study in
The equity funding package comprising private placement will raise a total of $1,951,369.33 by way of a placement of Allied Healthcare shares to investors and related parties of
Selumetinib, a small molecule MEK inhibitor, is an anti-cancer drug in Phase 2 development in a range of tumors. It was licensed from Array to AstraZeneca. The study
Scarlett has an experience of over 25 years in the pharmaceutical and biotechnology industry. Previously, he served as President and Chief Executive Officer of Proteolix, a biotechnology company
Nanotherapeutics will conduct studies to develop an improved formulation of diethylenetriaminepentaacetate (DTPA) and improve manufacturing its processes. DTPA can bind radioactive molecules to help the body remove them
Linaclotide is a guanylate cyclase type-C (GC-C) agonist. The company provided its efficacy and safety data from a Phase 3 program comprising two double-blind placebo-controlled trials. Over 1,600
AstraZeneca has filed a lawsuit against Handa for submitting an Abbreviated New Drug Application (ANDA) for a generic version of SEROQUEL XR to the US Food and Drug